Goldman Sachs
MNPR icon

Goldman Sachs’s Monopar Therapeutics MNPR Stock Holding History

Goldman Sachs’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
16,161
-18,549
-53% -$1.15M ﹤0.01% 4906
2026
Q1 		$1.9M Buy
34,710
+24,349
+235% +$1.47M ﹤0.01% 4585
2025
Q4 		$677K Buy
10,361
+3,836
+59% +$313K ﹤0.01% 5412
2025
Q3 		$533K Buy
+6,525
New +$292K ﹤0.01% 5473
2025
Q2 		– Sell
-18,480
Closed -$673K – 6299
2025
Q1 		$673K Buy
+18,480
New +$666K ﹤0.01% 4989

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs's MNPR Position: Q2 2026 in Review

Goldman Sachs reduced its Monopar Therapeutics (MNPR) stake by 53% in Q2 2026, selling an estimated $1.15M and leaving 16,161 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4906.

Goldman Sachs first reported a position in MNPR in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.9M in Q1 2026. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Goldman Sachs held 16,161 shares of Monopar Therapeutics worth $1.5M as of Q2 2026.
  • Goldman Sachs sold 18,549 Monopar Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Monopar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4906 holding.
  • Goldman Sachs first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Goldman Sachs's Monopar Therapeutics position peaked at $1.9M in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.